TrialThe Lancet. Neurology2021

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.

Daniel S Reich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.